Search
Home
News
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
AI
Innovation
Cybersecurity
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Analytics
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Home
News
Coins2Day 500
Coins2Day 500
Coins2Day Global 500
Coins2Day 500 Europe
Coins2Day China 500
Coins2Day SEA 500
Great Place To Work
Tech
Tech
AI
Innovation
Cybersecurity
Finance
Finance
Personal Finance
Real Estate
Economy
Investing
Banking
Crypto
Leadership
Leadership
Success
Future Of Work
Workplace Culture
C-Suite
CEO Initiative
Lifestyle
Lifestyle
Arts & Entertainment
Travel & Leisure
Health
Well
Education
Rankings
Rankings
Analytics
Multimedia
Multimedia
Live Media
Magazine
Newsletters
Video
Podcasts
Asia
Europe
Analytics
Roger Parloff
Stay informed with Roger Parloff’s coverage and analysis for Coins2Day.
Page 17 of 25
blogging
A law firm’s Internet alter ego
By
Investment Desk
Dickie Scruggs’ incredible shrinking wallet
By
Investment Desk
Scruggs guilty plea – but will he cooperate?
By
Staff Writer
Law firm bought ‘stolen’ Coke docs, official says
By
Crypto Correspondent
Ending software patents: Has the time come?
By
Crypto Correspondent
A Valentine’s gift: Vibrator sales legalized in Texas
By
Market Analyst
Scruggs may use stealth entrapment defense to bribery charge
By
News Correspondent
State Farm v. AG Jim Hood: Wild suit, wild questions, wild ending
By
Trading Desk
Ex-Milberg Weiss honcho to head NYC Bar
By
Financial Writer
Schulman sues Milberg Weiss for attorneys’ fees
By
News Correspondent
Brocade witness “recants”; Reyes seeks new trial
By
Market Analyst
Judge: Brocade CEO’s crimes caused no loss
By
Blockchain Reporter
Plaintiff suing Scruggs offers clues, poses questions
By
Industry Analyst
SCO’s prospects stay dicey v. Novell
By
Research Team
Pfizer wins big Celebrex ruling
By
Market Analyst